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cancer cases was based on the National Cancer Register con-
ducted by the Institute of Oncology in Poland. All calculations
were performed for 2006 (1 Euro = 3.8 PLN. RESULTS: Cost
of yearly treatment of one standard patient was 13.270 PLN
(€3.492) from public payer and 26.429 PLN (€6.955) from soci-
etal perspective respectively. Taking into account cervical cancer
prevalence in Poland (3.439 cases in 2003) and cost per each
case, the total burden of cervical cancer in 2006 was 45.635.530
PLN (€12.009.350) from public payer and 92.290.068 PLN
(€24.286.860) from societal perspective respectively. CONCLU-
SIONS: Cervical cancer is a fatal and costly disease. Indirect
costs are about 50% of total burden of cervical cancer in Poland
in 2006.
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OBJECTIVE: To evaluate the management and the management
cost of follow-up of women with abnormal Pap result in 5 coun-
tries (UK, Australia, Germany, Spain & Italy). METHODS: A
retrospective chart review of resource use was conducted in 33
centres within the ﬁve countries. Historical data was collected
on >3000 women with an abnormal Pap smear over a 2-year
treatment and follow-up period starting from year 2002. The
study population was stratiﬁed to include a minimum number of
subjects per cytology category: 35% mild, 25% moderate, 25%
severe dyskaryosis, and 15% cervical cancer. If not enough
cancer cases were enrolled in a country additional cases were
searched for. Unit costs for treatment were calculated from
country-speciﬁc cost databases. We compare overall and
between-countries overall age and age distribution; correlation
between cytology and histology; resource use and cost per his-
tology group after purchasing power parity adjustment.
RESULTS: Overall mean age of patients (n = 3380) was 36.3 y
old (min = 16 y, max = 90 y). Patients with histologically con-
ﬁrmed invasive cancer (n = 333) were on average 48.8 years (min
= 21 y, max = 85 y). Proportion of patients in each conﬁrmed
pre-cancer group was: CIN-1 = 17.1%; CIN-2 = 18.6%; CIN-3
= 29.9%. Negative evaluations after ﬁrst inspection and/or
biopsy were 24% and cancer cases seen and conﬁrmed were
9.9%. The correlation coefﬁcient between cytology and histol-
ogy ﬁndings overall was 62.6, but varied widely across countries.
Resource use such as number of pap smears per stage, colpo-
scopies, and LEEPs shows signiﬁcant differences across countries
and per histology stage (p < 0.05). The initiation of treatment
and type of treatment per histology stage varied considerably
within each country and across the aggregate database. CON-
CLUSION: Weak correlations between cytology and histology
across all countries were observed. Average cost per histology
varies by country and can be substantial. Large cost SDs per his-
tology stage indicate that it remains difﬁcult to standardise treat-
ment for early stages.
PCN38
“COST OF ILLNESS” ANALYSIS OF RENAL CELL CARCINOMA
Lang K1, Danchenko N1, Gondek K2, Schwartz B2,Thompson D1
1i3 Innovus, Medford, MA, USA, 2Bayer Pharmaceuticals Corporation,
West Haven, CT, USA
OBJECTIVES: Renal cell carcinoma (RCC) represents 2–3% of
all malignancies, and is associated with limited treatment options
and low survival rates (median survival for advanced metastatic
disease is estimated at 8–12 months). Despite its importance,
data on the economic burden of RCC are limited. METHODS:
A global, prevalence-based burden-of-illness model was devel-
oped and used to estimate the annual, societal economic burden
of RCC in selected European countries (UK, Spain, France, and
Germany). Key relationships represented in the model include
the annual numbers of patients treated for RCC by age group
and cancer stage; utilization of cancer-speciﬁc treatments; unit
costs of these treatments; work-days missed by these patients,
and wage rates. Local-area data sources were used to populate
the model parameters for each country. Methodological differ-
ences across countries resulting from differences in data avail-
ability are explained. RESULTS: The annual numbers of cases
of RCC include 24,834 in the UK, 3945 in Spain, 35,714 in
France, and 59,864 in Germany. Corresponding estimates of the
aggregate annual burden of RCC (€ 2005) are €541 million,
€41.8 million, €171 million, and €1.6 billion, respectively (per-
patient costs of €21,792, €10,607, €4781, and €26,397). Health
care costs account for between 66% and 89% of the burden in
each country, with lost productivity accounting for the remain-
der. Inpatient care for major surgery, radiofrequency ablation,
arterial embolization, systemic therapy (chemotherapy, radia-
tion, immunotherapy), and associated complications is the
largest driver of health care costs, accounting for approximately
80% or more of the burden in each country. Sensitivity analyses
indicated that results were most sensitive to assumptions regard-
ing health care utilization and unit costs of treatments. 
CONCLUSIONS: The economic burden of RCC in Europe is
substantial. Interventions to reduce the prevalence of RCC have
the potential to yield considerable economic beneﬁts to EU
health systems.
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OBJECTIVES: Trastuzumab (Herceptin®) combined to
chemotherapy has demonstrated signiﬁcant improvement in time
to progression and survival in metastatic breast cancer patient
overexpressing the receptor of the human growth factor (HER-
2). Herceptin® has recently received a new indication as an 
adjuvant therapy in localised invasive breast cancer and the 
cost-effectiveness of this new add-on therapy needs to be evalu-
ated. METHODS: An analytic Markov Model was established
based on the results of the pivotal clinical study (HERA) and
expert opinion to simulate for an early breast cancer patient 
the course of disease until death. The health states included 
loco-regional and distant recurrences (metastasis), cardiac events
(side-effects), disease free survival and death respectively. This
simulation model projected long-term clinical outcomes and
costs, of adding Herceptin® during one year sequentially to stan-
dard adjuvant therapy versus standard alone (observation).
According to current practices in France, Herceptin® was also
supposed to be used in case of distant recurrences in both arms.
Improvements in lifetime quality adjusted life years (QALY) were
also estimated. Transition probabilities were adjusted on HERA
results. Yearly costs of each health state came from published
sources and from detailed costs observed in one French Oncol-
ogy Centre (G.-F. Leclerc in Dijon). Direct costs and outcomes
were projected over patients’ lifetimes from a French Sickness
Fund perspective. They were both discounted at 3% annually.
Sensitivity analysis was performed. RESULTS: For 1000 patients
